Detalhe da pesquisa
1.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med
; 386(12): 1143-1154, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320644
2.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495879
3.
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
Breast Cancer Res Treat
; 195(1): 55-64, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35829935
4.
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Lancet
; 396(10257): 1090-1100, 2020 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966830
5.
A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
Oncologist
; 26(12): e2254-e2264, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34498344
6.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 379(22): 2108-2121, 2018 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30345906
7.
FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study.
Future Oncol
; 17(13): 1601-1609, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33415992
8.
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
Lancet Oncol
; 21(1): 60-72, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31806543
9.
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Breast Cancer Res Treat
; 167(3): 659-669, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29058175
10.
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Int J Gynecol Cancer
; 27(1): 50-58, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27749456
11.
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Breast Cancer Res Treat
; 160(1): 91-99, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27654971
12.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
N Engl J Med
; 366(2): 109-19, 2012 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22149875
13.
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study.
Breast Cancer Res
; 16(4): R73, 2014 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25005255
14.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Lancet Oncol
; 13(9): 869-78, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22884505
15.
Prognostic Factors and Survival Outcomes of Patients With Early HER2+ Breast Cancer Treated With Trastuzumab in a Brazilian Public Reference Center: A Real-World Study.
Clin Breast Cancer
; 23(8): 864-875.e7, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37802752
16.
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Breast Cancer Res Treat
; 133(1): 237-46, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22286314
17.
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
J Clin Oncol
; 40(7): 762-771, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34932394
18.
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
JAMA Oncol
; 8(8): 1190-1194, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653145
19.
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
J Clin Oncol
; 39(1): 79-89, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32822287
20.
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Clin Breast Cancer
; 21(3): 181-190.e2, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33148479